New Delhi: With Chinese enterprises starting to resume work amid the coronavirus outbreak in the country, the Narendra Modi government plans to adopt a “wait and watch” approach before announcing curbs on export of medicines, ThePrint has learnt.
A committee formed by the government last week to tackle “drug security concerns” has decided to closely monitor the situation after the Indian embassy in China informed the panel that several drugmakers there have resumed operations, said a source who is part of the panel.
The move came after Indian drugmakers informed the committee during a meet Monday that they have active pharmaceutical ingredients (APIs) stocks for the next two to three months.
APIs, or bulk drugs, are the raw materials required for the manufacture of medicines. For example, Paracetamol is the API for Crocin. Indian drugmakers import around 70 per cent of their total bulk drugs from China.
In 2018-19, Indian drugmakers imported bulk drugs and intermediates worth $2.4 billion from China, according to government data.
Chaired by Joint Drug Controller of India Eswara Reddy, the panel had earlier planned restrictions on the export of drugs to prevent shortage of medicines in the country.
Speaking to ThePrint, a senior Ministry of Commerce and Industry official, who is part of the committee, said the panel has taken the stock position and import trends from all pharma companies over an e-mail.
“They have an adequate amount of stocks to produce medicines for the next two to three months,” said the official, who did not wish to be named.
“Also, we have been informed through the Indian embassy in China that some of the drug-making units have resumed work. There is no need to panic now. Also, until today, the situation is under control and there is no need for announcing export curbs or ban. Let’s wait and watch, we have enough APIs in hand,” added the official.
Chinese resume work
According to a Chinese report, most enterprises in China have resumed production starting Monday.
In a circular, the Chinese government has reportedly “urged efforts to protect workers from getting infected and meanwhile resume production as soon as possible”.
Major hubs for API production are located far from Wuhan, the epicentre of the coronavirus outbreak. Other centres like Zhejiang, which hosts several drug-making units, “have also been approved by local authorities to resume work as of Feb. 8”.
57 APIs likely to go out of stock
On Monday, Indian drugmakers handed over a list of 57 APIs that are likely to go out of stock if China suffers a prolonged lockdown to the government committee. ThePrint has seen the list.
The list contains antibiotics such as Azithromycin, Amoxicillin, Ofloxacin, Gentamicin and Metronidazole, neuropathic drug Gabapentin, vitamin tablets and capsules such as B12, B1, B6, and E, female hormone progesterone and anti-cardiac arrest drug Atorvastatin, among others.
Apart from Reddy, other members of the committee include drug associations IDMA, IPA and OPPI, the Directorate General of Foreign Trade, the Indian Council of Medical Research, the National Pharmaceutical Pricing Authority and the Pharmaceutical Export Promotion Council of India.
IDMA, IPA and OPPI represent top domestic and foreign pharma companies operating in India, including Sun Pharma, Lupin, Zydus Cadila, Novartis and Glenmark, among others.
Why news media is in crisis & How you can fix it
You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.
You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.
We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And have just turned three.
At ThePrint, we invest in quality journalists. We pay them fairly. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is.
This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it.
If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous and questioning journalism. Please click on the link below. Your support will define ThePrint’s future.